198 related articles for article (PubMed ID: 35843284)
1. Allosteric Hotspots in the Main Protease of SARS-CoV-2.
Strömich L; Wu N; Barahona M; Yaliraki SN
J Mol Biol; 2022 Sep; 434(17):167748. PubMed ID: 35843284
[TBL] [Abstract][Full Text] [Related]
2. Repurposing of FDA-approved drugs against active site and potential allosteric drug-binding sites of COVID-19 main protease.
Yuce M; Cicek E; Inan T; Dag AB; Kurkcuoglu O; Sungur FA
Proteins; 2021 Nov; 89(11):1425-1441. PubMed ID: 34169568
[TBL] [Abstract][Full Text] [Related]
3. Impact of dimerization and N3 binding on molecular dynamics of SARS-CoV and SARS-CoV-2 main proteases.
Tekpinar M; Yildirim A
J Biomol Struct Dyn; 2022 Sep; 40(14):6243-6254. PubMed ID: 33525993
[TBL] [Abstract][Full Text] [Related]
4. Computational Identification of Possible Allosteric Sites and Modulators of the SARS-CoV-2 Main Protease.
DasGupta D; Chan WKB; Carlson HA
J Chem Inf Model; 2022 Feb; 62(3):618-626. PubMed ID: 35107014
[TBL] [Abstract][Full Text] [Related]
5. Allosteric Binding Sites of the SARS-CoV-2 Main Protease: Potential Targets for Broad-Spectrum Anti-Coronavirus Agents.
Alzyoud L; Ghattas MA; Atatreh N
Drug Des Devel Ther; 2022; 16():2463-2478. PubMed ID: 35941927
[TBL] [Abstract][Full Text] [Related]
6. Optimization Rules for SARS-CoV-2 M
Stoddard SV; Stoddard SD; Oelkers BK; Fitts K; Whalum K; Whalum K; Hemphill AD; Manikonda J; Martinez LM; Riley EG; Roof CM; Sarwar N; Thomas DM; Ulmer E; Wallace FE; Pandey P; Roy S
Viruses; 2020 Aug; 12(9):. PubMed ID: 32859008
[TBL] [Abstract][Full Text] [Related]
7. Molecular Docking of Azithromycin, Ritonavir, Lopinavir, Oseltamivir, Ivermectin and Heparin Interacting with Coronavirus Disease 2019 Main and Severe Acute Respiratory Syndrome Coronavirus-2 3C-Like Proteases.
Arouche TDS; Martins AY; Ramalho TC; Júnior RNC; Costa FLP; Filho TSA; Neto AMJC
J Nanosci Nanotechnol; 2021 Apr; 21(4):2075-2089. PubMed ID: 33500022
[TBL] [Abstract][Full Text] [Related]
8. Site mapping and small molecule blind docking reveal a possible target site on the SARS-CoV-2 main protease dimer interface.
Liang J; Karagiannis C; Pitsillou E; Darmawan KK; Ng K; Hung A; Karagiannis TC
Comput Biol Chem; 2020 Dec; 89():107372. PubMed ID: 32911432
[TBL] [Abstract][Full Text] [Related]
9. Allosteric Regulation of 3CL Protease of SARS-CoV-2 and SARS-CoV Observed in the Crystal Structure Ensemble.
Kidera A; Moritsugu K; Ekimoto T; Ikeguchi M
J Mol Biol; 2021 Dec; 433(24):167324. PubMed ID: 34717972
[TBL] [Abstract][Full Text] [Related]
10. In-silico pharmacophoric and molecular docking-based drug discovery against the Main Protease (Mpro) of SARS-CoV-2, a causative agent COVID-19.
Haider Z; Subhani MM; Farooq MA; Ishaq M; Khalid M; Akram MN; Khan RSA; Niazi AK
Pak J Pharm Sci; 2020 Nov; 33(6):2697-2705. PubMed ID: 33867348
[TBL] [Abstract][Full Text] [Related]
11. An extended conformation of SARS-CoV-2 main protease reveals allosteric targets.
Sun Z; Wang L; Li X; Fan C; Xu J; Shi Z; Qiao H; Lan Z; Zhang X; Li L; Zhou X; Geng Y
Proc Natl Acad Sci U S A; 2022 Apr; 119(15):e2120913119. PubMed ID: 35324337
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and Identification of Novel Potential Molecules Against COVID-19 Main Protease Through Structure-Guided Virtual Screening Approach.
El Bakri Y; Anouar EH; Ahmad S; Nassar AA; Taha ML; Mague JT; El Ghayati L; Essassi EM
Appl Biochem Biotechnol; 2021 Nov; 193(11):3602-3623. PubMed ID: 34324152
[TBL] [Abstract][Full Text] [Related]
13. Discovery of chebulagic acid and punicalagin as novel allosteric inhibitors of SARS-CoV-2 3CL
Du R; Cooper L; Chen Z; Lee H; Rong L; Cui Q
Antiviral Res; 2021 Jun; 190():105075. PubMed ID: 33872675
[TBL] [Abstract][Full Text] [Related]
14. In silico Study to Evaluate the Antiviral Activity of Novel Structures against 3C-like Protease of Novel Coronavirus (COVID-19) and SARS-CoV.
Chunduru K; Sankhe R; Begum F; Sodum N; Kumar N; Kishore A; Shenoy RR; Rao CM; Saravu K
Med Chem; 2021; 17(4):380-395. PubMed ID: 32720605
[TBL] [Abstract][Full Text] [Related]
15. Uncovering Flexible Active Site Conformations of SARS-CoV-2 3CL Proteases through Protease Pharmacophore Clusters and COVID-19 Drug Repurposing.
Pathak N; Chen YT; Hsu YC; Hsu NY; Kuo CJ; Tsai HP; Kang JJ; Huang CH; Chang SY; Chang YH; Liang PH; Yang JM
ACS Nano; 2021 Jan; 15(1):857-872. PubMed ID: 33373194
[TBL] [Abstract][Full Text] [Related]
16. Drug Repurposing for Candidate SARS-CoV-2 Main Protease Inhibitors by a Novel
Sencanski M; Perovic V; Pajovic SB; Adzic M; Paessler S; Glisic S
Molecules; 2020 Aug; 25(17):. PubMed ID: 32842509
[TBL] [Abstract][Full Text] [Related]
17. Near-physiological-temperature serial crystallography reveals conformations of SARS-CoV-2 main protease active site for improved drug repurposing.
Durdagi S; Dağ Ç; Dogan B; Yigin M; Avsar T; Buyukdag C; Erol I; Ertem FB; Calis S; Yildirim G; Orhan MD; Guven O; Aksoydan B; Destan E; Sahin K; Besler SO; Oktay L; Shafiei A; Tolu I; Ayan E; Yuksel B; Peksen AB; Gocenler O; Yucel AD; Can O; Ozabrahamyan S; Olkan A; Erdemoglu E; Aksit F; Tanisali G; Yefanov OM; Barty A; Tolstikova A; Ketawala GK; Botha S; Dao EH; Hayes B; Liang M; Seaberg MH; Hunter MS; Batyuk A; Mariani V; Su Z; Poitevin F; Yoon CH; Kupitz C; Sierra RG; Snell EH; DeMirci H
Structure; 2021 Dec; 29(12):1382-1396.e6. PubMed ID: 34403647
[TBL] [Abstract][Full Text] [Related]
18. Novel Small-Molecule Scaffolds as Candidates against the SARS Coronavirus 2 Main Protease: A Fragment-Guided in Silico Approach.
Augustin TL; Hajbabaie R; Harper MT; Rahman T
Molecules; 2020 Nov; 25(23):. PubMed ID: 33255326
[TBL] [Abstract][Full Text] [Related]
19. Establishing an Analogue Based In Silico Pipeline in the Pursuit of Novel Inhibitory Scaffolds against the SARS Coronavirus 2 Papain-Like Protease.
Hajbabaie R; Harper MT; Rahman T
Molecules; 2021 Feb; 26(4):. PubMed ID: 33672721
[TBL] [Abstract][Full Text] [Related]
20. Artificial intelligence based virtual screening study for competitive and allosteric inhibitors of the SARS-CoV-2 main protease.
Charles S; Edgar MP; Mahapatra RK
J Biomol Struct Dyn; 2023; 41(24):15286-15304. PubMed ID: 36943715
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
